quarta-feira, maio 04, 2005
Abbott procura aprovação para nova formulação do Kaletra
E o aumento de preço será ... ?
"ABBOTT SUBMITS APPLICATION TO U.S. FDA FOR A NEW FORMULATION OF KALETRA (LOPINAVIR/RITONAVIR)"
ABBOTT PARK, Ill., May 3, 2005 - Abbott announced today that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the approval of a new, more convenient tablet formulation of its protease inhibitor (PI) Kaletra (lopinavir/ritonavir). The tablet was developed using a proprietary novel melt-extrusion technology intended to allow patients to take fewer tablets per dose as part of their treatment regimen. In addition, the tablet would not require refrigeration, as the current soft-gel capsule formulation does.
Mais acerca da tecnologia Meltrex aqui.